Retrospective cohort studies with IL‐1 inhibition with the short‐acting IL‐1 receptor antagonist anakinra in COVID‐19 patients have shown promising results [40] and is now being tested in several controlled trials, such as the CAN‐COVID study [29, 41, 42, 43]. This evidence concerns the gene IL1B and COVID-19.